Pay Attention to "ZVSA" (tmrw...)

Here's why you should do your due dilligence on the following stock. There are a number of short-term and long-term factors that are worth paying attention to.͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌

Put "ZVSA" on Your Radar! ­ Hey Folks   Get ready for another exciting idea!   ZyVersa is a clinical stage specialty biopharmaceutical company with two licensed proprietary product platforms invented by top tier research scientists at University of Miami Miller School of Medicine.    The two platforms are dedicated to the treatment of inflammatory and renal diseases. Keep in mind that just the anti-inflammatory market is expected to reach $152 billion by 2033.   This means that there's plenty of growth opportunities for ZyVersa to capitalize on in their areas of expertise.   How are they planning to do this? They currently have 5 different pharmaceutical candidates designed to tackle the anti-inflammatory market and 3 different ones for the renal disease market.   The approval of anyone of these could turn this well positioned biotech player into an overnight success story.   Though the long-term potential of biotech is compelling, the short-term catalysts are what make this sector truly electrifying!   Just take a look at ZVSA for instance... The company has over a dozen preclinical and clinical catalysts lined up, each of which have the potential to get the bulls excited.   Among these, FDA approvals stand out as the most critical milestones, as they mark pivotal moments in a drug's journey.   Each pharmaceutical candidate must navigate a rigorous, highly regulated process, with decisions made on predefined dates that can significantly impact the company's trajectory. The result?   The generation of massive hype waves that can often create strong momentum for a stock!   In the case of ZyVersa, there are three big FDA catalysts scheduled for 2025 including a pre-IND meeting, IND Filing, and phase 1 trial.   Catalysts enthusiasm might explain some of the recent price action spikes we've been seeing for ZVSA... There have been three major ones over the past few months, one of which pushed the stock to local highs of $4.33 before falling back down.   It also doesn't hurt that ZVSA has an insanely low float...   Only 2.34 million according to MarketWatch. This means that the presence of just a few bulls can turn the party into a full blown fiesta! Anyways... That's all for now!   Until Next Time, -Damian P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!  (standard carrier data/text rates apply) ZIPTRADER LLC 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA You've received it because you've subscribed to our newsletter or are a member of ZipTraderU. This email was sent to phanxuanhoa60.trade1357@blogger.com BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service.See Our Advertisement/Sponsored Stock Disclaimer. View in browser | Unsubscribe